BioAffinity Technologies (BIAF) Stock Surges 55% as CyPath Lung Targets Lung Cancer Survivors

TLDR

• BIAF stock surged over 55% on Tuesday after the company announced a new potential use for its CyPath Lung test in lung cancer survivors
• The company is exploring CyPath Lung for detecting cancer recurrence in patients who have completed curative-intent treatment
• Over 680,000 Americans were living with a prior lung cancer diagnosis as of January 1, 2025
• Trading volume exceeded 17 million, well above the 3-month average of 5.91 million
• AI analyst Spark rates BIAF as Underperform with a $5.50 price target, citing cash burn and revenue decline

BioAffinity Technologies stock was trading up more than 55% on Tuesday after the company put out a press release announcing it is advancing CyPath Lung for use in lung cancer survivors.

bioAffinity Technologies, Inc., BIAF

The stock opened the day already elevated, having climbed 65.57% in premarket trading. That followed a 6.37% drop the session before. Year-to-date, BIAF is still down 74.24%, and has lost 95.72% over the past 12 months.

The company said it is exploring CyPath Lung as a tool for cancer recurrence surveillance in patients who have finished curative-intent treatment.

… Continue reading the full article at the original source below.